Large Controlled Trials Should Be Exempt From Financial Disclosure - PhRMA
Executive Summary
Investigators and institutions involved in large controlled studies should receive the exemption from FDA's financial disclosure rule already granted for large open studies and treatment protocols, the Pharmaceutical Research & Manufacturers of America asserted in a July 31 petition for reconsideration of the Feb. 2 final rule.